Last reviewed · How we verify

Bupivacaine Spinal 0,5% Heavy - bolus

Centre of Postgraduate Medical Education · FDA-approved active Small molecule

Bupivacaine Spinal 0,5% Heavy - bolus is a Local anesthetic (amide class) Small molecule drug developed by Centre of Postgraduate Medical Education. It is currently FDA-approved for Spinal anesthesia for surgical procedures of the lower abdomen, pelvis, and lower extremities, Spinal anesthesia for obstetric procedures. Also known as: Single bolus.

Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia.

Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Spinal anesthesia for surgical procedures of the lower abdomen, pelvis, and lower extremities, Spinal anesthesia for obstetric procedures.

At a glance

Generic nameBupivacaine Spinal 0,5% Heavy - bolus
Also known asSingle bolus
SponsorCentre of Postgraduate Medical Education
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that penetrates nerve membranes and reversibly binds to sodium channels from the intracellular side, inhibiting sodium influx and depolarization. The 0.5% heavy formulation (isobaric or hyperbaric depending on preparation) is administered intrathecally for spinal anesthesia, providing prolonged sensory and motor blockade in the lower body and lower extremities. The 'heavy' designation typically indicates the solution is hyperbaric (denser than cerebrospinal fluid), affecting its distribution in the spinal canal.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bupivacaine Spinal 0,5% Heavy - bolus

What is Bupivacaine Spinal 0,5% Heavy - bolus?

Bupivacaine Spinal 0,5% Heavy - bolus is a Local anesthetic (amide class) drug developed by Centre of Postgraduate Medical Education, indicated for Spinal anesthesia for surgical procedures of the lower abdomen, pelvis, and lower extremities, Spinal anesthesia for obstetric procedures.

How does Bupivacaine Spinal 0,5% Heavy - bolus work?

Bupivacaine blocks sodium channels in nerve fibers, preventing the initiation and propagation of action potentials to produce local anesthesia.

What is Bupivacaine Spinal 0,5% Heavy - bolus used for?

Bupivacaine Spinal 0,5% Heavy - bolus is indicated for Spinal anesthesia for surgical procedures of the lower abdomen, pelvis, and lower extremities, Spinal anesthesia for obstetric procedures.

Who makes Bupivacaine Spinal 0,5% Heavy - bolus?

Bupivacaine Spinal 0,5% Heavy - bolus is developed and marketed by Centre of Postgraduate Medical Education (see full Centre of Postgraduate Medical Education pipeline at /company/centre-of-postgraduate-medical-education).

Is Bupivacaine Spinal 0,5% Heavy - bolus also known as anything else?

Bupivacaine Spinal 0,5% Heavy - bolus is also known as Single bolus.

What drug class is Bupivacaine Spinal 0,5% Heavy - bolus in?

Bupivacaine Spinal 0,5% Heavy - bolus belongs to the Local anesthetic (amide class) class. See all Local anesthetic (amide class) drugs at /class/local-anesthetic-amide-class.

What development phase is Bupivacaine Spinal 0,5% Heavy - bolus in?

Bupivacaine Spinal 0,5% Heavy - bolus is FDA-approved (marketed).

What are the side effects of Bupivacaine Spinal 0,5% Heavy - bolus?

Common side effects of Bupivacaine Spinal 0,5% Heavy - bolus include Hypotension, Bradycardia, Headache (post-dural puncture), Nausea, Urinary retention, Transient neurological symptoms.

What does Bupivacaine Spinal 0,5% Heavy - bolus target?

Bupivacaine Spinal 0,5% Heavy - bolus targets Voltage-gated sodium channels and is a Local anesthetic (amide class).

Related